Email: info@apollotherapeutics.comTranslating innovative science into therapeutic potential

Latest Apollo Projects

Bispecific mAb targeting and activating through CEA / 4-1BB for immuno-oncology

By Richard Butt

Bispecific mAb targeting and activating through CEA / 4-1BB for immuno-oncology

a collaboration with Prof Kerry Chester, University College London, and Cyclogenix

Prof Kerry Chester, University College London Cancer Institute and Cyclogenix have fused an anti-CEA antibody that recognises tumour cells with a novel cyclotide that binds the T-cell activating receptor 4-1BB as a potential immune-oncology therapeutic agent.  Based on this research, Apollo, University College London and Cyclogenix teams are now collaborating to identify and optimise a bispecific agent for testing in preclinical in vitro and in vivo studies.


|